Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Last trade$7.20
Day change-$0.28 (-3.74%)
Day range$7.12 – $7.55
Volume469,516
Market cap$627M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$626.92M
Price / earnings
—
Price / book
1.87×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.16×
Profitability
Earnings per share
-$0.55
Return on assets
-13.36%
Return on equity
-13.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
33.72×
Quick ratio
33.72×
Cash ratio
31.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$45.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMMX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$10.4M
$7.12M
$4.82M
$5.17M
$3.08M
$2.75M
$2.71M
$3.61M
Research and development
$5.54M
$5.33M
$5.98M
$5.73M
$4.58M
$3.97M
$1.98M
$1.37M
Total operating expenses
$15.95M
$12.46M
$10.8M
$10.89M
$7.66M
$6.72M
$4.68M
$4.99M
Operating income
-$15.95M
-$12.46M
-$10.8M
-$10.89M
-$7.66M
-$6.72M
-$4.68M
-$4.99M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$13.93M
-$11.54M
-$10.09M
-$10.68M
-$7.58M
-$6.61M
-$4.53M
-$4.8M
Income taxes
$0
$14.32K
$0
$11.27K
$7.72K
$8.91K
$9.82K
$10.79K
Net income
-$13.93M
-$11.56M
-$10.09M
-$10.69M
-$7.59M
-$6.62M
-$4.54M
-$4.81M
Net income attributable to common shareholders
-$13.93M
-$11.56M
-$10.04M
-$10.69M
-$7.59M
-$6.62M
-$4.53M
-$4.81M
EBITDA
-$15.85M
-$12.37M
-$10.71M
-$10.84M
-$7.57M
-$6.66M
-$4.64M
-$4.97M
Basic earnings per share
-$0.19
-$0.18
-$0.18
-$0.27
-$0.24
-$0.22
-$0.15
-$0.15
Diluted earnings per share
-$0.19
-$0.18
-$0.18
-$0.27
-$0.24
-$0.22
-$0.15
-$0.15
Recent news
Company coverage with links to the original publishers.
Tenet Healthcare is projected to report Q3 2026 earnings of $4.60 per share (up 24.3% YoY) on revenues of $5.47 billion (up 3.5% YoY). The company's Ambulatory Care segment is expected to drive growth with 8.4% revenue increase and 9.3% adjusted EBITDA growth. However, hospital patient days may decline 3.7% with increased utilization costs partially offsetting gains. The stock has an Earnings ESP of +11.11% and Zacks Rank #3, suggesting a likely earnings beat.
Pomerantz Law Firm is investigating Immix Biopharma for potential securities fraud after discovering that its newly appointed Chief Medical Officer, Richard Graydon, was actually Ronald L. Fischer, a fugitive wanted for a 2005 rape charge who had evaded authorities for over 20 years. Following the revelation, Immix's stock price dropped 14.15% on July 20, 2026.
EquipmentShare.com Inc. (EQPT) faces a securities fraud lawsuit after allegedly making false statements about terminating related-party transactions with founder-controlled entities. A short-seller report revealed undisclosed transactions netting founders at least $77 million, causing the stock to plummet 34.5% below its IPO price. Investors who purchased shares between January 23 and June 23, 2026, may be eligible to recover losses.
The Portnoy Law Firm has launched an investigation into possible securities fraud at Immix Biopharma after discovering that an executive operating under the alias 'Richard Graydon' was actually Ronald Fischer, a fugitive wanted in Rhode Island. The company terminated the officer on July 17, 2026, claiming the separation was unrelated to his activities. Following the disclosure, Immix's stock price declined approximately 10.83%.
Block & Leviton is investigating Immix Biopharma for potential securities law violations after discovering that an executive operating under the name 'Richard Graydon' was actually a Rhode Island fugitive named Ronald Fischer using a false identity. The company terminated the individual on July 17, 2026, stating it was unrelated to his work activities. Immix shares fell approximately 10.83% following the news report.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.